1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Lupin MD on a biosimilars play fused around Japan 'anchor'

 
• By Anju Ghangurde

Lupin may have been slow off the block in the biosimilars space in emerging markets compared with some of its Indian peers, but the Mumbai-based firm is hoping that a strategy centred around its "anchor market" Japan may more than compensate as well as propelling its entry into the US and Europe.

Lupin may have been slow off the block in the biosimilars space in emerging markets compared with some of its Indian peers, but the Mumbai-based firm is hoping that a strategy centred around its "anchor market" Japan may more than compensate as well as propelling its entry into the US and Europe.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia